In cases where top AD genes were assessed in the CRC group, KRAS, TTN, and TP53 genes were mutated in more CRCs patients than ADs, while ELAC2, MARCH6, and TMEM132B genes were mutated in more AD patients than in CRCs, with a minimum of 10% difference. This evidence concerns the gene MARCHF6 and Alzheimer disease.